Last edition
News about "ADC therapy"
Hansoh Pharma Reports Positive Phase 3 Results for Ris-Rez in China
Hansoh Pharma reported positive phase 3 results for Ris-Rez in China, while GSK advances development across lung cancer, prostate cancer and other solid tumors.
ADC Therapy | 31/07/2026 | By News Bureau
Zai Lab Secures China Approval for TIVDAK
Zai Lab has received China NMPA approval for TIVDAK (tisotumab vedotin), the first Antibody-Drug Conjugate (ADC) approved for previously treated recurrent or metastatic cervical cancer in China. The approval is supported by phase 3 innovaTV 301 trial data demonstrating a statistically significant overall survival benefit.
ADC Therapy | 09/06/2026 | By News Bureau | 103
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy